Evidence mapPaperPMID 41480001Full record

ReviewWorld journal of cardiology2025

Pentadecanoic acid (C15:0) and cardiovascular disease: A narrative review.

Joseph Mercola

Abstract readReview
In one paragraph

Review in World journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Joseph MercolaIndependent Researcher, Midwestern University, Downers Grove, IL 60515, United States. drm@mercola.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide despite major advances in prevention and treatment. The odd-chain saturated fatty acid pentadecanoic acid (C15:0), primarily obtained from dairy fat, has been associated with cardiometabolic benefits. To summarize recent advances in understanding the role of pentadecanoic acid (C15:0) in CVD biology and risk, and to identify knowledge gaps and future research priorities. A narrative review was conducted, drawing on 115 PubMed-indexed studies on odd-chain fatty acids (OCFAs) and cardiovascular outcomes, as well as illustrative mechanistic studies of C15:0. This narrative review synthesized evidence from approximately 115 PubMed-indexed studies on OCFAs and cardiovascular outcomes, along with mechanistic studies of C15:0, identified through targeted searches in PubMed, Scopus, and Web of Science from January 2000 through May 2025.

Indexed as

Cardiometabolic healthCardiovascular diseaseDairy fatInflammationInsulin sensitivityMitochondrial functionOdd-chain saturated fatty acidsPentadecanoic acid

Identifiers

PMID41480001
PMCPMC12754079

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.